This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
Top Wall Street analysts changed their outlook on top names. See analyst ratings page for full list. DRI, JANX, and more mentioned.
Read original at benzingaStocks · News reference
Janux Therapeutics shares are trading higher after Wolfe Research upgraded the stock from Peer Perform to Outperform rating and announced a $23 price target.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 24, 2026, 5:28 PM
- Checked
- Aug 24, 2026, 5:28 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target
Read original at benzingaGuggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $58 to $55.
Read original at benzinga